Revenue beat and guidance rose, but care margins deteriorated sharply

Revenue materially beat expectations. Second-quarter revenue was $652.5 million, roughly 9% above the published consensus of $597.7 million, while adjusted EPS was $0.02 versus consensus of approximately negative $0.01. The upside was concentrated in the Performance Suite, which grew to $484.5 million from $267.9 million, while Specialty Technology and Services revenue declined to $78.2 million from $81.4 million. (Segment revenue table)

The headline beat came with substantially weaker underlying care economics. The Medical Expense Ratio rose to 95.3% from 80.0%, meaning nearly all Performance Suite revenue was absorbed by claims costs; excluding the discontinued Evolent Care Partners business, the comparable ratio still worsened to 95.3% from 84.9%. Adjusted EBITDA fell 25% year over year to $28.1 million, and the margin halved to 4.3%. (Medical Expense Ratio table; Adjusted EBITDA reconciliation)

Full-year guidance moved up, but mostly because revenue visibility improved rather than current profitability. Revenue guidance increased from the prior $2.4-$2.6 billion range to $2.6-$2.7 billion, while Adjusted EBITDA guidance shifted from approximately $110-$140 million to $120-$135 million: a higher floor, but only a modestly higher midpoint and a narrower range. (Business Outlook; prior-quarter guidance) The planned oncology Performance Suite launch, expected to cover 1.5 million lives and generate approximately $300 million of annualized revenue, is the main new growth catalyst, but it remains subject to regulatory approvals and is not yet operating. (Business Outlook)

Cash conversion and leverage remain the main constraints on the positive read. Evolent used $10.3 million of operating cash in the first half, ended with $141.5 million of cash and restricted cash, and carried $966.5 million of net long-term debt; accounts receivable also rose to $449.1 million from $309.9 million at year-end. (Cash Flow statement; Balance Sheet) Management's 2027 outlook—over 25% revenue growth and at least $150 million of midpoint Adjusted EBITDA—is encouraging, but it depends on improved Performance Suite margins, expense reductions, and debt-reduction actions that are still being evaluated. (Business Outlook)

Net: a real revenue and guidance beat, but not a clean operating beat. The result is better than the market expected on sales and near-term earnings, yet the sharp medical-cost deterioration, lower EBITDA margin, negative cash flow, and heavy debt load prevent this from reading as a broad fundamental improvement.